IAG Bio-Partnering Team to Attend Anlgonordic in London, United Kingdom 24 May 2018
Dr. Olga Kubassova, CEO of IAG will attend Anglonordic in London, United Kingdom to discuss the increasing need for collaboration between the investors and biotechnology companies in development of new compounds and to introduce IAG’s platforms, targeted development strategies and risk-sharing business model.
IAG Bio-Partnering division is an independent investment division of IAG that works to build a diversified investment portfolio of innovative life science companies at various stages of clinical development.
IAG biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.
The scope of discussions for this conference include:
– Development of clinical stage assets
– IP acquisition from the academic partners and biotech companies
– Investment partnerships
– Strategic collaborations
To find out more about IAG Bio-Partnering services or to schedule a meeting during Bio€quity, please send an email to firstname.lastname@example.org.
Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors. The main conference room has a biotech investment focus; the technology room features devices, diagnostics, delivery and development tools. One-to-one meetings take place throughout the day. The Exhibition and quiet area double up for lunch service and refreshments are available all day. To find out more about the conference click here
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com